Populära just nu
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) meddelade den 18 april 2024 att B...
Redeye presents its preview of Sedana Medical’s Q1 2024 report, due on April 25.
Adj. EBITA SEK 180m (-16% vs. ABGSCe 214m) Consensus full-year EBITA should come down by mid-to-high...
Redeye strengthens its positive view of Vertiseit following a solid Q1 report, new long-term goals, ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye is encouraged to see progress in Impact Coatings’ Chinese coating center.
We cut '24e-'26e adj. EBITA by 8-4% Should break seven-quarter negative org.
Solid Q1 with 33% ARR growth and 15% adj. EBITDA margin Raising '24e-'26e ARR by ~1%, EBITDA by 19-1...
Försäljningen i Q4 minskade något jämfört med samma period i fjol.
Fastighetsmarknaden har en alltmer balanserad antydan och fastighetsbolaget fortsätter att stärka up...
The recorded sales growth is 0% in local currency due to an extended headwind for the Genetics busin...
SRV publishes its Q1/24 figures on Thursday 25th of April.
VIMAB Group är en industrikoncern verksamma inom miljö, elektrifiering och near-shoring.
Redeye provides its initial take on Vitec’s Q1 2024 report, which came in slightly below our estimat...
Redeye provides its initial take on ADDvise’s Q1 2024 report, which came in broadly below our estima...